Brown Miller Wealth Management LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Brown Miller Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% in the 4th quarter, Holdings Channel reports. The firm owned 20,242 shares of the company’s stock after purchasing an additional 569 shares during the period. Johnson & Johnson accounts for about 1.1% of Brown Miller Wealth Management LLC’s investment portfolio, making the stock its 26th biggest holding. Brown Miller Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,927,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Northwest Wealth Management LLC raised its position in Johnson & Johnson by 19.3% in the 4th quarter. Northwest Wealth Management LLC now owns 2,362 shares of the company’s stock valued at $342,000 after purchasing an additional 382 shares during the last quarter. Renasant Bank raised its position in Johnson & Johnson by 12.4% during the 4th quarter. Renasant Bank now owns 3,943 shares of the company’s stock worth $570,000 after buying an additional 436 shares during the last quarter. King Wealth Management Group raised its position in Johnson & Johnson by 2.1% during the 4th quarter. King Wealth Management Group now owns 15,558 shares of the company’s stock worth $2,250,000 after buying an additional 314 shares during the last quarter. Blume Capital Management Inc. raised its position in Johnson & Johnson by 4.3% during the 4th quarter. Blume Capital Management Inc. now owns 67,808 shares of the company’s stock worth $9,806,000 after buying an additional 2,777 shares during the last quarter. Finally, May Barnhard Investments LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $379,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Leerink Partners cut their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $162.93 on Friday. The stock has a market cap of $392.28 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company’s 50-day moving average price is $154.60 and its 200 day moving average price is $156.38. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.